Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BMP4 | P12644 | 4/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 13/20 | 0.66 |
| ▸ | ACVRL1 | P37023 | 9/20 | 0.66 |
| ▸ | BMPR1B | O00238 | 8/20 | 0.66 |
| ▸ | BMPR1A | P36894 | 5/20 | 0.66 |
| ▸ | ACVR1B | P36896 | 5/20 | 0.66 |
| ▸ | KDR | P35968 | 5/20 | 0.62 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.62 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.62 |
| ▸ | FLT1 | P17948 | 2/20 | 0.52 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | YES1 | P07947 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.52 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.52 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.52 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24787719 | 0.88 | BMP4 (0.78) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL11953448 | 0.85 | BMP4 (1.00) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL24409662 | 0.85 | BMP4 (0.74) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL2059669 | 0.80 | BMP4 (0.70) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL16025969 | 0.79 | ACVR1 (1.00) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL11953444 | 0.78 | BMP4 (1.00) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL12779932 | 0.77 | BMP4 (0.62) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL2059674 | 0.77 | BMP4 (0.68) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL29388057 | 0.77 | PRKAB1 (1.00) | BMP4ACVR1ACVRL1BMPR1BBMPR1A | |
| SCHEMBL14671953 | 0.77 | PRKAB1 (1.00) | BMP4ACVR1ACVRL1BMPR1BBMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-10179111-B2 | Treating soft tissue via controlled drug release | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2019-01-15 | — | — | US | disclosed |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-19 | — | — | US | disclosed |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-01-19 | — | — | US | disclosed |
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-15 | — | — | US | disclosed |
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2016-09-15 | — | — | US | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2014-01-09 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-8507501-B2 | Inhibitors of the BMP signaling pathway | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012100229-A2 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009114180-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | THE GENERAL HOSPITAL CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263117-A1 | COMPOSITIONS AND METHODS FOR CARDIOVASCULAR DISEASE | APOB, BMP1, LDLR | BMP4 8/4885ACVR1 18/4885ACVRL1 24/4885 |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | ALK, ACVR2A, ACVR1 | BMP4 64/4885ACVR1 3/4885ACVRL1 6/4885 |
| US-10179111-B2 | Treating soft tissue via controlled drug release | BMP2, BMP1, BMP6 | BMP4 6/4885ACVR1 16/4885ACVRL1 25/4885 |
| US-20110053930-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | BMP4 4/4885ACVR1 9/4885ACVRL1 13/4885 |
| US-20170014349-A1 | TREATING SOFT TISSUE VIA CONTROLLED DRUG RELEASE | BMP2, BMP1, BMP6 | BMP4 6/4885ACVR1 16/4885ACVRL1 25/4885 |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | BMP4 7/4885ACVR1 13/4885ACVRL1 22/4885 |
| US-20140011805-A1 | INHIBITORS OF THE BMP SIGNALING PATHWAY | BMP1, BMP2K, BMP2 | BMP4 4/4885ACVR1 9/4885ACVRL1 13/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | BMP4 17/4885ACVR1 16/4885ACVRL1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.